Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of programs. The company revealed the changes on Thursday … ...
Alumis (ALMS) stock gains as Oppenheimer initiates coverage with an Outperform recommendation, citing a valuation disconnect. Read more here.
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...
In his first confirmation hearing, Robert F. Kennedy Jr. tried to distance himself from his past statements on abortion and ...
Guidance for 2025 from UPS falls short of estimates. Altria Group, the maker of tobacco products, posts quarterly earnings in line with expectations. Fourth-quarter per-share earnings of 80 cents top ...
Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...
Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...
A summary of current health news including Cigna's profit decline, Robert F. Kennedy Jr.'s Senate hearings, an Ebola outbreak ...
Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback